These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 2300353

  • 1. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC.
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [Abstract] [Full Text] [Related]

  • 2. Serum CA 125 levels in preoperative evaluation of pelvic masses.
    Vasilev SA, Schlaerth JB, Campeau J, Morrow CP.
    Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX, Schwartz PE, Li XG, Yang Z.
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [Abstract] [Full Text] [Related]

  • 4. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
    Durdević S, Segedi D, Vejnović T, Radeka G.
    Med Pregl; 1992 Jul; 45(7-8):262-5. PubMed ID: 1344453
    [Abstract] [Full Text] [Related]

  • 5. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX, Schwartz PE, Li FQ.
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
    O'Connell GJ, Ryan E, Murphy KJ, Prefontaine M.
    Obstet Gynecol; 1987 Dec; 70(6):930-2. PubMed ID: 3479735
    [Abstract] [Full Text] [Related]

  • 7. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N, Bast RC, Knapp RC, Tjernberg B, Zurawski VR.
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [Abstract] [Full Text] [Related]

  • 8. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
    Padungsutt P, Thirapagawong C, Senapad S, Suphanit I.
    Anticancer Res; 2000 Mar; 20(2B):1291-5. PubMed ID: 10810437
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V.
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [Abstract] [Full Text] [Related]

  • 11. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Buković D.
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [Abstract] [Full Text] [Related]

  • 12. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
    Roman LD, Muderspach LI, Burnett AF, Morrow CP.
    J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
    Patsner B, Mann WJ, Chalas E.
    Obstet Gynecol; 1988 Jun; 71(6 Pt 1):949-50. PubMed ID: 3163416
    [No Abstract] [Full Text] [Related]

  • 14. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ, Oram DH, Bast RC.
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [Abstract] [Full Text] [Related]

  • 15. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H, Schieder K, Neunteufel W, Bieglmayer C.
    Neoplasma; 1989 Sep; 36(4):473-8. PubMed ID: 2770933
    [Abstract] [Full Text] [Related]

  • 16. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M, Wong GY, Nisselbaum JS, Almadrones L, Hoskins WJ, Rubin SC.
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [Abstract] [Full Text] [Related]

  • 17. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
    Gadducci A, Ferdeghini M, Prontera C, Moretti L, Pellagatta L, Bianchi R, Fioretti P.
    J Nucl Biol Med (1991); 1991 Jun; 35(1):33-7. PubMed ID: 1657201
    [Abstract] [Full Text] [Related]

  • 18. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM.
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [Abstract] [Full Text] [Related]

  • 19. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
    Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC.
    Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
    [Abstract] [Full Text] [Related]

  • 20. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
    Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Facchini V, Bianchi R, Fioretti P.
    J Nucl Med Allied Sci; 1989 Apr; 33(1):32-6. PubMed ID: 2746365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.